This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: AAP BIDU DO LLL TSLA

Stocks in this article: AAP BIDU DO LLL TSLA

Solarwinds (SWI) was downgraded at Needham to hold from buy. Company missed expectations and has several moving parts with the MSP acquisition, Needham said.

Tesla Motors (TSLA) was upgraded at Deutsche Bank to buy from hold. $160 price target. Capitalizing on inherent advantages of electric vehicles, Deutsche Bank said.

Vantiv (VNTV) was upgraded at UBS to buy and given a $30 price target. Strong visibility and an attractive valuation, said UBS.

Vantiv (VNTV) was downgraded at Wells Fargo to market perform from outperform. Valuation call, as the company is seeing lower sales, Wells Fargo said.

Vertex Pharmaceuticals (VRTX) was downgraded at UBS to neutral and given a $83 price target. Safety concerns about VX-135, UBS said.

VCA Antech (WOOF) upgraded at Piper Jaffray to overweight from neutral. Price target was increased to $32. Favorable industry trends, improving margins, and upcoming buyback programs drive the bull case, Piper Jaffray said.

Zynga (ZNGA) was downgraded at Needham to hold from buy. Now expected to generate negative cash flow, Needham said.

Stock Comments / EPS Changes

Arch Capital Group (ACGL) numbers were raised at UBS. Estimates were raised to reflect the second-quarter earnings beat and the expectation of higher loss reserve releases, said UBS. Price target goes to $56.

Biogen Idec (BIIB) numbers were increased at BMO Capital. Estimates were boosted through 2014. Company continues to execute well with Tecfidera, BMO Capital said. Market Perform rating and new $237 price target.

BioMarin (BMRN) estimates were raised at UBS. Reflect the earnings beat, said UBS. Price target is $67.

Bristol-Myers (BMY) estimates were cut at UBS. Estimates were reduced given the voluntary OTC recalls and investments in the Eliquis launch, said UBS. Price target is $48.

Borg Warner (BWA) numbers were raised at Citigroup. Estimates were increased given margin expansion and potential for cash deployment, said Citigroup. Price target goes to $106.

Cameron International (CAM) estimates were cut at UBS. Estimates were reduced given integration delays with OneSubsea, said UBS. Price target is $75.

Chubb Corp. (CB) estimates were raised at UBS. Reflect the second-quarter beat and a decrease in the combined ratio outlook, said UBS. Price target is $96.

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs